Ezetimibe/rosuvastatin
Ezetimibe (top) and rosuvastatin (bottom)
Combination of
EzetimibeHypolipidemic agent
RosuvastatinStatin
Clinical data
Trade namesRidutrin,Cholerose Plus, Lipocomb, Rosuzet, others[1][2]
AHFS/Drugs.comMultum Consumer Information
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol.[6][7] In some countries it is sold as a kit or a pack containing two distinct pills.[8][1]

The combination was approved for medical use in the United States in March 2021.[5]

Medical uses

Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.[9]

Pharmacology

Ezetimibe/rosuvastatin combines two lipid-lowering therapies with distinct actions to achieve greater lowering of LDL-C that either agent alone.

Together, these drugs cause a net decrease in hepatocyte intracellular cholesterol leading to scavenging of LDL particles from the blood via upregulation of the LDL receptor.

References

  1. 1 2 "Rosuvastatin international". Drugs.com. 3 February 2020. Retrieved 17 February 2020.
  2. 1 2 "Ezetimibe/rosuvastatin: List of nationally authorised medicinal products" (PDF). European Medicines Agency (EMA). 21 March 2018. PSUSA/00010271/201707. Retrieved 17 February 2020.
  3. 1 2 "TGA eBS - Product and Consumer Medicine Information Licence".
  4. ↑ "EZESTAT COMPOSITE PACK (Pharmacor Pty Ltd)". Department of Health and Aged Care. Archived from the original on 18 March 2023.
  5. 1 2 "Roszet: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 March 2021.
  6. ↑ "Ridutrin SmPC" (PDF). Medicines Data Bank. 30 May 2019. Retrieved 17 February 2020.
  7. ↑ Willihnganz MJ, Gurevitz SL, Clayton BD (November 2021). "HMG-CoA Reductase Inhibitor Combination Products". Clayton's Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. p. 344. ISBN 978-0-323-81258-0.
  8. ↑ "Rosuzet Composite Pack". NPS MedicineWise. 8 January 2020. Retrieved 17 February 2020.
  9. ↑ Sharretts J (23 March 2021). "NDA Approval Letter for Roszet (rosuvastatin and ezetimibe)" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration.
  10. 1 2 "DailyMed - ROSZET- rosuvastatin and ezetimibe tablet ROSZET (- rosuvastatin and ezetimibe tablet". dailymed.nlm.nih.gov. Retrieved 14 January 2024.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.